Symrise AG Makes Strategic Equity Investment in US Biotech Firm Cellibre
Symrise AG has made a strategic equity investment in US biotech firm Cellibre, which specializes in precision fermentation. This partnership aims to enhance the development of natural flavor ingredients and bioactive cosmetic substances. By collaborating on manufacturing technologies, Symrise seeks to expand its portfolio in taste-balancing solutions and clean beauty ingredients, reinforcing its leadership in sustainable, fermentation-derived products and supporting long-term market competitiveness.
Symrise AG has announced a strategic equity investment in Cellibre, a US-based biotechnology company specializing in precision fermentation. This partnership will allow Symrise to accelerate the development of high-quality, natural flavor ingredients and bioactive cosmetic substances. By collaborating on manufacturing technologies for globally relevant ingredients, Symrise aims to expand its portfolio in taste-balancing solutions and clean beauty active ingredients. The move reinforces Symrise’s leadership in sustainable, fermentation-derived ingredients and supports its long-term competitiveness in the market. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Symrise AG published the original content used to generate this news brief on October 22, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
